Results 191 to 200 of about 12,266 (204)
Some of the next articles are maybe not open access.

PDE5 inhibitors: are there differences?

The Canadian journal of urology, 2006
The introduction of oral agents for the treatment of erectile dysfunction (ED) has revolutionized the treatment of men with erection problems of all severities and etiologies. Sildenafil, available on the world market since 1998 was joined in 2003 by tadalafil and vardenafil as effective save and reliable oral agents.
openaire   +1 more source

The Utility of PDE5 Inhibitors After Radical Prostatectomy

2009
Radical prostatectomy of any form (open, laparoscopic, or robotic) has become a widely performed procedure for patients with clinically localized prostate cancer. This procedure may be associated with treatment-specific sequelae affecting health-related quality of life, with urinary incontinence and erectile dysfunction being the most prevalent.
SALONIA , ANDREA   +3 more
openaire   +2 more sources

Sildenafil Citrate, the Classic PDE5 Inhibitor

2005
In 1988, a new class of drugs was heralded by the release of sildenafil citrate, an orally administered, potent, and selective phosphodiesterase type 5 (PDE5) inhibitor.
openaire   +1 more source

PDE5 Inhibitors

2010
R. Hamish McAllister-Williams   +199 more
openaire   +1 more source

[Nitrates and PDE5 inhibitors: pharmaceutical care].

Pharmazie in unserer Zeit, 2010
Miriam, Ude   +2 more
openaire   +1 more source

Home - About - Disclaimer - Privacy